论文部分内容阅读
目的 :观察中风 1号治疗缺血性卒中的疗效。方法 :112例缺血性卒中患者随机分为 2组。治疗组口服中风 1号颗粒 ,每次 15 g;对照组口服醒脑再造丸 ,每次 9g。均每日 3次 ,14日为 1个疗程 ,连用 2个疗程。同时检测内皮素 (ET 1)、一氧化氮 (NO)、T细胞亚群、红细胞免疫粘附促进因子 (EFAF)及红细胞免疫粘附抑制因子 (EFAI)等指标。结果 :治疗组总有效率 (89.2 9% )明显高于对照组 (5 5 .36 % ) ;治疗组治疗后 ET 1、NO、EFAF、EFAI、T细胞亚群 (OKT3、OKT4、OKT8)及 OKT4/ OKT8较治疗前均有明显改善 (P均 <0 .0 5 ) ,改善幅度大于对照组 (P均 <0 .0 5 )。结论 :在缺血性卒中时存在内皮素、一氧化氮平衡紊乱及神经免疫调制功能障碍 ,中风 1号对其有明显改善作用。
Objective: To observe the curative effect of stroke No.1 on ischemic stroke. Methods: One hundred and twelve patients with ischemic stroke were randomly divided into two groups. The treatment group oral stroke No. 1 particles, each 15 g; control group oral Xingnao Pills, each 9g. 3 times a day, 14 days for a course of treatment, once every 2 courses. At the same time, the indexes of endothelin (ET 1), nitric oxide (NO), T lymphocyte subsets, erythrocyte immune adhesion promoting factor (EFAF) and erythrocyte immune adherence inhibitory factor (EFAI) were detected. Results: The total effective rate (89.2 9%) in the treatment group was significantly higher than that in the control group (55.36%). The ET 1, NO, EFAF, EFAI and T cell subsets (OKT3, OKT4 and OKT8) OKT4 / OKT8 than before treatment were significantly improved (P all <0.05), the improvement was greater than the control group (P <0.05). CONCLUSION: Endothelin, nitric oxide balance disorders and neuroimmunological dysfunction exist in ischemic stroke. Stroke 1 markedly improves on them.